Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals

Prediction of hepatocellular carcinoma (HCC) development after sustained virological response (SVR) is clinically important, and the usefulness of noninvasive markers for prediction HCC have been reported. The aim of this study was to compare the prediction accuracy for HCC development by noninvasive markers. A total of 346 patients with chronic hepatitis C without history of HCC who achieved SVR through direct‐acting antivirals were included. Magnetic resonance elastography (MRE) and serum fibrosis markers were measured 12 weeks after the end of treatment, and the subsequent HCC development was examined. The mean observation period was 26.4 ± 7.9 months, and 24 patients developed HCC. Area under the receiver operating characteristic curve of liver stiffness by MRE, Wisteria floribunda agglutinin‐positive mac‐2 binding protein and FIB‐4 for predicting HCC within 3 years was 0.743, 0.697 and 0.647, respectively. The 1/2/3‐year rates of HCC development in patients with liver stiffness ≥3.75 KPa were 6.6%, 11.9% and 14.5%, whereas they were 1.4%, 2.5% and 2.5% in patients with liver stiffness <3.75 KPa (P < 0.001). Multivariate analysis revealed that liver stiffness ≥3.75 was an independent predictive factor for HCC development (hazard ratio, 3.51; 95% confidence interval, 1.24‐9.99). In subgroup analysis, there were 132 patients who were <73 years old and had liver stiffness <3.75 KPa, and no HCC development was observed in these patients. Diagnostic accuracy for predicting HCC development was higher in MRE than serum fibrosis markers and measurement of liver stiffness by MRE could identify patients with high and low risk of HCC development after SVR.

[1]  Y. Hiasa,et al.  Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  A. Tsubota,et al.  Efficacy of direct‐acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  P. Johnson,et al.  The impact of HCV eradication by direct‐acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[4]  M. Kurosaki,et al.  Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  Yoshiyuki Suzuki,et al.  Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  M. Kurosaki,et al.  Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  N. Enomoto,et al.  Wisteria floribunda agglutinin‐positive Mac‐2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct‐acting antivirals for hepatitis C virus , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  M. Kurosaki,et al.  Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  M. Kurosaki,et al.  Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group , 2018, Journal of Gastroenterology.

[10]  D. Samuel,et al.  The impact of treatment of hepatitis C with DAAs on the occurrence of HCC , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[11]  C. Sirlin,et al.  Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis , 2018, Hepatology.

[12]  Robert M. Marks,et al.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. , 2018, Radiology.

[13]  G. Dore,et al.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.

[14]  Aya Kamaya,et al.  2017 Version of LI-RADS for CT and MR Imaging: An Update. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  S. Kakinuma,et al.  Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. , 2017, Journal of hepatology.

[16]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[17]  K. Matsuura,et al.  Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  T. Ishikawa,et al.  Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[19]  Armando Manduca,et al.  Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations. , 2016, Radiology.

[20]  H. Hayashi,et al.  MR elastography of the liver at 3.0 T in diagnosing liver fibrosis grades; preliminary clinical experience , 2016, European Radiology.

[21]  M. Kurosaki,et al.  Wisteria floribunda agglutinin positive human Mac‐2‐binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[22]  Darrick K. Li,et al.  Impact of hepatitis C virus eradication on hepatocellular carcinogenesis , 2015, Cancer.

[23]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  M. Kurosaki,et al.  Prospective comparison of real‐time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  H. Toyoda,et al.  Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC , 2014, Hepatology International.

[26]  N. Enomoto,et al.  α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C , 2013, Hepatology.

[27]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[28]  A. Manduca,et al.  Assessment of hepatic fibrosis with magnetic resonance elastography. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.